Fexinidazole

Kathryn Dzintars, Pharm.D., BCPS
Fexinidazole is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • First-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to T. brucei gambiensein patients 6 years of age and older who weigh at least 20 kg.
  • Due to decreased efficacy observed in patients with severe second-stage HAT, fexinidazole should only be used in these patients if no other options are available.
  • This drug was developed as part of the Drugs for Neglected Diseases initiative.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • First-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to T. brucei gambiensein patients 6 years of age and older who weigh at least 20 kg.
  • Due to decreased efficacy observed in patients with severe second-stage HAT, fexinidazole should only be used in these patients if no other options are available.
  • This drug was developed as part of the Drugs for Neglected Diseases initiative.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 19, 2022